Business Update & Financial Outlook

Vaccines: Exceptional growth driven by GARDASIL • • GARDASIL sales of $2.5B increased 53% year-over-year primarily driven by strong global demand, particularly in China - - China growth is benefitting from the expanded indication of GARDASIL 9 to females ages 9 to 45 Strong ongoing pediatric launch of VAXNEUVANCE GARDASIL. [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] $1.7B +40% GARDASIL.9 [Human Papillomavirus 9-valent Vaccine, Recombinant] $2.5B +53% Growth rates exclude the impact of foreign exchange. $1.2B +78% 2Q21 2Q22 2Q23 MERCK 13

View entire presentation